What are the general options for the combined medication regimen of enzalutamide/enzalutamide (Anchortan)?

Enzalutamide/Enzalutamide (Enzalutamide), as an androgen receptor antagonist, has been widely used in the treatment of prostate cancer, especially for castration-resistant prostate cancer (CRPC) with significant efficacy. In actual clinical applications, enzalutamide is often used in combination with other drugs to enhance therapeutic effects, reduce drug resistance, and improve patients' quality of life. The choice of combination therapy depends primarily on the patient's specific condition and response to treatment.

A common combination therapy is enzalutamide combined with a chemotherapy drug, especially docetaxel.Docetaxel. Docetaxel, one of the standard chemotherapy drugs used to treat metastatic prostate cancer, works by inhibiting the division of cancer cells. When combined with enzalutamide, the combined effect of treatment may be enhanced, particularly in patients who have developed castration-resistant prostate cancer. The combination of docetaxel and enzalutamide can inhibit the growth of tumor cells through multiple pathways at the same time, thereby improving the cure rate and prolonging the survival of patients.

Another common combination regimen is enzalutamide combined with radiation therapy. When local tumor progression is obvious in some patients, radiotherapy can effectively relieve tumor symptoms and reduce tumor size. Enzalutamide further enhances the effect of radiotherapy by inhibiting the androgen signaling pathway. The combination of radiotherapy and enzalutamide can treat local tumors and systemic tumors simultaneously, providing a more comprehensive effect.

In addition, the combined application of enzalutamide and immune checkpoint inhibitors has also begun to be explored in recent years. Immune checkpoint inhibitors, such as pembrolizumab, can activate the patient's immune system to help identify and attack tumor cells. When combined with enzalutamide, this regimen may further enhance the immune response, particularly in patients with immune-tolerant prostate cancer.

Reference materials:https://www.xtandi.com/